Biologic interventions for fatigue in rheumatoid arthritis-Reference-Cited by-同舟云学术

Biologic interventions for fatigue in rheumatoid arthritis

Published:2016-06-06 Issue:6 Volume:2016 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Almeida Celia¹,Choy Ernest HS²,Hewlett Sarah¹,Kirwan John R³,Cramp Fiona¹,Chalder Trudie⁴,Pollock Jon¹,Christensen Robin⁵

Affiliation:

1. University of the West of England; Faculty of Health & Life Sciences; Courtyard Building, BRI Bristol UK BS2 8HW

2. Cardiff University School of Medicine; Section of Rheumatology, Division of Infection and Immunity; Tenovus Building Heath Park Cardiff UK CF14 4XN

3. University of Bristol, Bristol Royal Infirmary; Rheumatology Unit; The Courtyard Marlborough Street Bristol UK BS2 8 HW

4. Institute of Psychiatry, Psychology & Neuroscience, King's College London; Chronic Fatigue Service, Department of Psychological Medicine; Weston Education Centre Cutcombe Road London UK SE5 9RH

5. Copenhagen University Hospital, Bispebjerg og Frederiksberg; Musculoskeletal Statistics Unit, The Parker Institute; Nordre Fasanvej 57 Copenhagen Denmark DK-2000

Publisher

Wiley

Subject

Pharmacology (medical)

Reference108 articles.

1. Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study;Alten;BMC Musculoskeletal Disorder,2011

2. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis;Bae;BMC Musculoskeletal Disorder,2013

3. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX;Choy;Rheumatology,2012

4. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks;Cohen;Arthritis and Rheumatism,2006

5. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy;Keystone;Arthritis and Rheumatism,2008

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic mapping review of clinical guidelines for the management of fatigue in long-term physical health conditions;Disability and Rehabilitation;2024-06-04

2. Why does malaise/fatigue occur? Underlying mechanisms and potential relevance to treatments in rheumatoid arthritis;Expert Review of Clinical Immunology;2024-01-19

3. Efficacy of pharmacological interventions: a systematic review informing the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases;RMD Open;2023-12

4. Potential Mechanism of Fatigue Induction and Its Management by JAK Inhibitors in Inflammatory Rheumatic Diseases;Journal of Inflammation Research;2023-09

5. Treat-to-Target in Pediatric Rheumatic Diseases;Current Rheumatology Reports;2023-08-16